Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. More Details
+ 1 more risk
Weak fundamentals or lack of information.
Share Price & News
How has Lattice Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LBL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LBL exceeded the Canadian Biotechs industry which returned 56.5% over the past year.
Return vs Market: LBL exceeded the Canadian Market which returned -3.6% over the past year.
Price Volatility Vs. Market
How volatile is Lattice Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StShould You Be Concerned About Lattice Biologics Ltd.'s (CVE:LBL) Historical Volatility?
10 months ago | Simply Wall StIntroducing Lattice Biologics (CVE:LBL), The Stock That Zoomed 150% In The Last Year
1 year ago | Simply Wall StDoes Lattice Biologics Ltd. (CVE:LBL) Have A High Beta?
Is Lattice Biologics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Lattice Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lattice Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of LBL's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Lattice Biologics regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Lattice Biologics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lattice Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of LBL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Lattice Biologics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Lattice Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LBL is currently unprofitable.
Growing Profit Margin: LBL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LBL is unprofitable, but has reduced losses over the past 5 years at a rate of 46% per year.
Accelerating Growth: Unable to compare LBL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LBL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: LBL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Lattice Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: LBL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: LBL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LBL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LBL has less than a year of cash runway if free cash flow continues to grow at historical rates of 62.7% each year.
What is Lattice Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LBL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LBL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LBL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LBL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LBL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Guy Cook (55 yo)
Mr. Guy S. Cook has been the Chief Executive Officer of Lattice Biologics Ltd. since December 23, 2013 and also serves as its President since December 2015. Mr. Cook served as the Chief Executive Officer a ...
CEO Compensation Analysis
Compensation vs Market: Guy's total compensation ($USD360.00K) is above average for companies of similar size in the Canadian market ($USD171.35K).
Compensation vs Earnings: Guy's compensation has been consistent with company performance over the past year.
|Chairman of the Board||6.83yrs||US$360.00k||35.78% |
|Independent Director||26.75yrs||no data||0.096% |
|Independent Director||3.33yrs||no data||2.08% |
|Chair of the Scientific Advisory Board||3.33yrs||no data||no data|
Experienced Board: LBL's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LBL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.2%.
Lattice Biologics Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Lattice Biologics Ltd.
- Ticker: LBL
- Exchange: TSXV
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$3.847m
- Shares outstanding: 128.22m
- Website: https://www.latticebiologics.com
- Lattice Biologics Ltd.
- 512 East Madison Avenue
- Suite 101
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LBL||TSXV (TSX Venture Exchange)||Yes||Voting Common Shares||CA||CAD||Dec 2015|
|B5G2||DB (Deutsche Boerse AG)||Yes||Voting Common Shares||DE||EUR||Dec 2015|
|LBLT.F||OTCPK (Pink Sheets LLC)||Yes||Voting Common Shares||US||USD||Dec 2015|
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. Th ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/27 00:04|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.